SCHEMBL7075768

SCHEMBL7075768

O=S(=O)(N=S1CCN(S(=O)(=O)c2ccc(Cl)cc2)CC1)c1ccc(Oc2cnccn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
LMNA P02545 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TP53 P04637 1/20 0.39
KMT2A Q03164 2/20 0.39
LTA4H P09960 1/20 0.38
PTGS2 P35354 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTT P42858 1/20 0.38
POLB P06746 1/20 0.37
MAPK1 P28482 1/20 0.37
ATM Q13315 1/20 0.37
MAPT P10636 1/20 0.37
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7075332 0.87 MAPT (0.41) ALDH1A1LMNAL3MBTL1KMT2ASMN1; SMN2
SCHEMBL7111882 0.80 KMT2A (0.54) ALDH1A1LMNAL3MBTL1TP53KMT2A
SCHEMBL7081280 0.80 KMT2A (0.44) ALDH1A1LMNAL3MBTL1KMT2ASMN1; SMN2
SCHEMBL7075335 0.79 ALDH1A1 (0.58) ALDH1A1LMNAL3MBTL1KMT2ASMN1; SMN2
SCHEMBL7082715 0.76 PKM (0.48) ALDH1A1LMNAL3MBTL1KMT2ASMN1; SMN2
SCHEMBL7076865 0.74 LMNA (0.43) ALDH1A1LMNAL3MBTL1KMT2ASMN1; SMN2
SCHEMBL7076851 0.72 KMT2A (0.45) ALDH1A1LMNAL3MBTL1KMT2ASMN1; SMN2
SCHEMBL7080644 0.72 LMNA (0.49) ALDH1A1LMNAL3MBTL1KMT2ASMN1; SMN2
SCHEMBL7080232 0.71 NOTUM (0.49) ALDH1A1LMNAL3MBTL1TP53KMT2A
SCHEMBL7080184 0.71 PKM (0.46) ALDH1A1LMNAL3MBTL1TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030158186-A1 Compositions and methods for treating heart failure CYTOKINETICS, INCORPORATED 2003-08-21 US disclosed
WO-2003059265-A2 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE CYTOKINETICS, INC. (US) 2003-07-24 WO disclosed
WO-2003059265-A2 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE CYTOKINETICS, INC. (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158186-A1 Compositions and methods for treating heart failure MYH2, TNNI3, MYLK2 ALDH1A1 3435/4885SLC6A2 1717/4885SLC6A4 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.